Alpha 1 Lung Disease Market Size is valued at USD 4.13 Billion in 2022 and is predicted to reach USD 19.93 Billion by the year 2031 at a 19.33% CAGR during the forecast period for 2023-2031.
Alpha-1 Antitrypsin Deficiency is a genetic disorder in which the body does not make enough of a protein known as alpha-1 antitrypsin. This protein is very important for keeping the lungs safe from damage caused by inflammation. People who don't get enough of this protein are more likely to get lung illnesses like emphysema and chronic obstructive pulmonary disease (COPD). Some people who don't have enough Alpha-1 Antitrypsin may also have trouble with their liver. The main goal of treatment is to control the symptoms; in some cases, augmentation therapy may be used to restore the missing protein. Adults usually have pulmonary difficulties, and both adults and children can have skin problems. In paediatric cases of AATD, liver illness, rather than COPD, is the most common form of the disease.
However, during the pandemic, the global supply chain for medications and medical supplies encountered difficulties. This could have hampered Alpha-1 sufferers' access to drugs and treatments. The pandemic may have slowed ongoing clinical trials and research on Alpha-1 Antitrypsin Deficiency. This could have an impact on the timetables for developing and approving novel treatments.
Competitive Landscape
Some Major Key Players In The Alpha 1 Lung Disease Market:
- AstraZeneca
- Boehringer Ingelheim
- Roche
- Novartis
- Pfizer
- Merck
- Bristol-Myers Squibb
- Takeda Pharmaceutical
- CSL Behring
- Vertex Pharmaceuticals
- Amgen
- Sanofi
- GlaxoSmithKline
- Gilead Sciences
- Eli Lilly
- AbbVie,
- Johnson & Johnson
- Teva Pharmaceutical
- Audentes Therapeutics
- Regeneron Pharmaceuticals
- LFB Biomedicaments
- Grifols
- Kamada Ltd
- Others
Market Segmentation:
The Alpha 1 Lung Disease Market is segmented according to disease type, treatment type, route of administration, distribution channel, and end-user. As per the disease type, the market is segmented as Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, and Others. The treatment type segment includes Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others. The route of administration segment consists of Inhalation, Injectable, and Oral. The distribution channel segment includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The end-user segment includes Hospitals, Homecare, specialty Clinics, and Others.
Based On Disease Type, The Chronic Obstructive Pulmonary Disease (COPD) Segment Is Accounted As A Major Contributor In The Alpha 1 Lung Disease Market.
The Chronic Obstructive Pulmonary Disease (COPD) category is expected to hold a major share in the global Alpha 1 Lung Disease Market in 2022. Alpha-1 Antitrypsin Deficiency (Alpha-1) is a hereditary condition that can result in chronic obstructive pulmonary disease (COPD). COPD is a progressive lung illness characterized by airflow limitation, and those with Alpha-1 are more likely to develop it. Ongoing COPD research and development activities, especially those linked with Alpha-1, can potentially lead to the development of new and more effective treatment alternatives.
The Hospital Segment Witnessed A Rapid Expansion.
The hospital segment is expected to grow at a rapid rate in the global Alpha 1 Lung Disease Market. As awareness rises and diagnostic skills improve, there may be an increase in patient admissions to hospitals for Alpha-1 Lung Disease diagnosis and care. Hospitals are critical in providing diagnostic services for genetic abnormalities such as Alpha-1. In this setting, demand for genetic testing and diagnostic services may fuel growth. Hospitals provide both inpatient and outpatient care, ranging from urgent interventions to long-term therapy for people with Alpha-1-related lung illnesses.
In The Region, The North America Alpha 1 Lung Disease Market Holds A Significant Revenue Share.
The North America Alpha 1 Lung Disease Market is expected to record the maximum market revenue share in the near future. The Alpha-1 Lung Disease market drivers in North America are influenced by a variety of factors, including healthcare infrastructure, research and development, patient awareness, and regulatory considerations. The Europe alpha-1 antitrypsin deficiency disease market is also predicted to grow rapidly. Efforts to raise awareness about genetic abnormalities and uncommon diseases, such as Alpha-1 Antitrypsin Deficiency, have the potential to lead to earlier discovery and diagnosis in the European community. Growth and development in healthcare infrastructure across the European region can contribute to improved access to diagnostic services and specialized treatment for Alpha-1 Lung Disease.
Recent Developments:
- In May 2023, Kamada Pharmaceuticals announced Glassia's Swiss commercial approval for the treatment of alpha-1 antitrypsin insufficiency. Swissmedic has approved Glassia [Alpha-1 Proteinase Inhibitor (Human)] for prolonged augmentation and maintenance therapy in patients with clinically evident emphysema due to severe familial alpha-1 antitrypsin deficiency illness.
Alpha 1 Lung Disease Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 4.13 Billion |
|
Revenue Forecast In 2031 |
USD 19.93 Billion |
|
Growth Rate CAGR |
CAGR of 19.33 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences, Eli Lilly, AbbVie, Johnson & Johnson, Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals, LFB Biomedicaments, Grifols, Kamada Ltd, and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
